Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.52 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.52 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5235970 | 0.92 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL15140566 | 0.87 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL458805 | 0.87 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL9411411 | 0.87 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL9372786 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL4203844 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL1430074 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL21551129 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL618588 | 0.86 | SMN1; SMN2 (0.71) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL10089216 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0956865-B2 | MEDICINES COMPRISING Rho KINASE INHIBITOR | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-08-18 | — | — | EP | disclosed |
| EP-0956865-B1 | MEDICINES COMPRISING Rho KINASE INHIBITOR | MITSUBISHI PHARMA CORP (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-6906061-B2 | Pharmaceutical agent containing Rho kinase inhibitor | MITSUBISHI PHARMA CORPORATION (JP) | 2005-06-14 | — | — | US | disclosed |
| US-20030134775-A1 | Pharmaceutical agent containing Rho kinase inhibitor | UEHATA MASAYOSHI (JP) | 2003-07-17 | — | — | US | disclosed |
| US-6451825-B1 | FOR THERAPY OF HYPERTENSION, A THERAPEUTIC AGENT OF ANGINA PECTORIS, A SUPPRESSIVE AGENT OF CEREBROVASCULAR CONTRACTION, ASTHMA, PERIPHERAL CIRCULATION DISORDER, AS PROPHYLACTIC AGENT OF IMMATURE BIRTH, A THERAPEUTIC AGENT OF ARTERIOSCLEROSIS | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-17 | — | — | US | disclosed |
| US-20020032148-A1 | Pharmaceutical agent containing Rho kinase inhibitor | MITSUBISHI PHARMA CORPORATION (JP) | 2002-03-14 | — | — | US | disclosed |
| US-6218410-B1 | ADMINISTERING A PHARMACEUTICALLY EFFECTIVE AMOUNT OF A RHO KINASE INHIBITOR COMPRISING AMIDE COMPOUND FOR INHIBITING RHO KINASE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-0956865-A1 | MEDICINES COMPRISING Rho KINASE INHIBITOR | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134775-A1 | Pharmaceutical agent containing Rho kinase inhibitor | ROCK1, RHOA, ARHGDIA | SMN1; SMN2 1184/4885NPC1 2258/4885RAB9A 404/4885 |
| US-20020032148-A1 | Pharmaceutical agent containing Rho kinase inhibitor | ROCK1, RHOA, ARHGDIA | SMN1; SMN2 1184/4885NPC1 2258/4885RAB9A 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.